{"schema_version":"1.0","type":"article","title":"藥王保衛戰，默沙東撞上專利牆","url":"https://drugnews.com.tw/articles/2026-10-12-keytruda-qlex-subcutaneous-delivery-value.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-12-keytruda-qlex-subcutaneous-delivery-value.md","lang":"zh-Hant","date":"2026-10-12","publish_at":"2026-10-12T08:00:00+08:00","updated_at":"2026-10-12","category":"商業分析系列","topic":"商業分析系列","tags":["Keytruda","QLEX","PD-1","皮下注射","藥物遞送","默沙東"],"summary":"一支藥撐起半家公司的營收，專利卻不會因此多給幾年。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"Keytruda靜脈輸注與QLEX皮下注射的給藥時間比較","url":"https://drugnews.com.tw/assets/articles/keytruda-qlex-subcutaneous-delivery-value/FIG01_ZH_R1.png"},{"alt":"PD-1抗體作用與玻尿酸酶幫助皮下遞送的分工示意","url":"https://drugnews.com.tw/assets/articles/keytruda-qlex-subcutaneous-delivery-value/FIG02_ZH_R1.png"},{"alt":"病人時間、醫院容量與支付方費用的採用條件","url":"https://drugnews.com.tw/assets/articles/keytruda-qlex-subcutaneous-delivery-value/FIG03_ZH_R1.png"},{"alt":"QLEX占2026年第二季KEYTRUDA與QLEX組合收入約5.5%","url":"https://drugnews.com.tw/assets/articles/keytruda-qlex-subcutaneous-delivery-value/FIG04_ZH_R1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/keytruda-qlex-subcutaneous-delivery-value/FIG01_ZH_R1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-12）。藥王保衛戰，默沙東撞上專利牆。https://drugnews.com.tw/articles/2026-10-12-keytruda-qlex-subcutaneous-delivery-value.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-10-12-keytruda-qlex-subcutaneous-delivery-value-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}